{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T05:42:33Z","timestamp":1675316553277},"reference-count":17,"publisher":"ALUNA","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wiad Lek"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:p>The aim: Show the efficacy of the Tiotropium \/ olodaterol combination in real clinical practice. \nMaterials and methods: 100 patients with the diagnosis of COPD were included onto the study during the period of 2019-2020, an average age was 64.09\u00b11.94 years, 66 were men (66 %) and 34 were women (34 %). There were 68 % of smokers with the average smoking experience of 24.44\u00b14.84 pack-years. Average COPD duration was 9.35\u00b12.42 years. There were 3 visits in the study \u2013 visit 1 (baseline), visit 2 (4-6 weeks) visit 3 (1 year). Source documentation was assessed at visit 1 and visit 3 for amount of exacerbations, antibiotic, glucocorticosteroid, methylxanthines use; mMRC and CAT were assessed at all visits. \nResults: Combined therapy with tiotropium\/olodaterol improves clinical course of COPD, which is characterized by the significant decreased of the amount of exacerbations (2.63\u00b10.29 to 1.63\u00b10.21) and hospital admissions (1.2\u00b10.2 t\u043e 0.37\u00b10.11). Improvement of symptoms and amount of exacerbation leads to much less use of antibiotics and glucocorticosteroids. A part of patients that used antibiotics decreased from 86\u00b16.9 % to 67\u00b19.3 %, amount of antibiotic courses from 1.37\u00b10.17 t\u043e 0.88\u00b10.15, duration of treatment with antibiotics from 10.85\u00b11.53 to 6.12\u00b11.17 days. Part of the patients that used glucocorticosteroids decreased from 50\u00b19.9 % t\u043e 30\u00b19.1 %, duration of treatment with antibiotics reduced from 3.97\u00b11.06 t\u043e 1.86\u00b10.91 days. There also was a tendency towards a lesser used of methylxanthines. Combined therapy with tiotropium\/olodaterol significantly decreased symptoms of COPD according to the mMRC (2.3\u00b10.14 to 1.87\u00b10.15) and \u0421\u0410\u0422 (23.28\u00b11.71 to 15.77\u00b11.58). \nConclusions: Tiotropium\/olodaterol combination showed its efficacy in real clinical practice. There was significant reduction in amount of exacerbation and antibiotic, gluco\u00accorticosteroid use during the study, which was also accompanied by the reduction is symptoms.<\/jats:p>","DOI":"10.36740\/wlek202212110","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T17:34:46Z","timestamp":1675272886000},"page":"2953-2957","source":"Crossref","is-referenced-by-count":0,"title":["EFFICACY OF COMBINATION OF TIOTROPIUM\/OLODATEROL IN PATIENTS WITH COPD IN REAL CLINICAL PRACTICE"],"prefix":"10.36740","volume":"75","author":[{"given":"Kostiantyn D.","family":"Dmytriiev","sequence":"first","affiliation":[{"name":"VINNYTSIA NATIONAL PIROGOV MEMORIAL MEDICAL UNIVERSITY, VINNYTSIA, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuriy M.","family":"Mostovoy","sequence":"additional","affiliation":[{"name":"VINNYTSIA NATIONAL PIROGOV MEMORIAL MEDICAL UNIVERSITY, VINNYTSIA, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oleksandr","family":"Dobrovanov","sequence":"additional","affiliation":[{"name":"SLOVAK MEDICAL UNIVERSITY AND UNIVERSITY HOSPITAL, BRATISLAVA, SLOVAK REPUBLIC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nataliia S.","family":"Slepchenko","sequence":"additional","affiliation":[{"name":"VINNYTSIA NATIONAL PIROGOV MEMORIAL MEDICAL UNIVERSITY, VINNYTSIA, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22436","published-online":{"date-parts":[[2022]]},"reference":[{"key":"ref0","unstructured":"1. Nazarchuk O., Dmytriiev D., Dmytriiev K. et al. Characteristics of infectious complications in critically ill patients. Wiad Lek. 2018;71(9):1784-1792."},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Mathers C.D., Loncar D. Projections of Global Mortality and Burden of Disease from 2002 to 2030. PLoS Medicine. 2006. doi:10.1371\/journal.pmed.0030442.","DOI":"10.1371\/journal.pmed.0030442"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Dmytriiev K., Mostovoy Y., Slepchenko N. et al. \u201cSmoking\u201d vs \u201cnon-smoking\u201d COPD: how dramatic is the difference? European Respiratory Journal. 2020;56(64):1043. doi: 10.1183\/13993003. congress-2020.1043.","DOI":"10.1183\/13993003.congress-2020.1043"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Salvi S. Tobacco smoking and environmental risk factors for chronic obstructive pulmonary disease. Clin. Chest Med. 2014;35:17\u201327.","DOI":"10.1016\/j.ccm.2013.09.011"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Silverman E.K. Genetics of COPD. Annu Rev Physiol. 2020;82:413-431. doi: 10.1146\/annurev-physiol-021317-121224.","DOI":"10.1146\/annurev-physiol-021317-121224"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Dmytriiev K., Mostovoy Y., Slepchenko N. et al. Can reversibility determine clinical course in patients with COPD? European Respiratory Journal 2020;56:1041; doi: 10.1183\/13993003.congress-2020.1041.","DOI":"10.1183\/13993003.congress-2020.1041"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Kralinsky K., Pisarcikova M., Dobrovanov O., Babela R. Protocol for the diagnosis, management and treatment of pediatric patients with COVID-19 according to the recommendations of the Slovakian Pediatric Society. Ros Vestn Perinatol Pediat. 2020; 65(5):93-99. doi:10.21508\/1027-4065-2020-65-5-93-99.","DOI":"10.21508\/1027-4065-2020-65-5-93-99"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Dmytriiev D., Dobrovanov O., Kralinsky K., Babela R. Adaptive supportive ventilation in a child with coronavirus pneumonia and diabetes mellitus. Ros Vestn Perinatol Pediat. 2020; 65(5):66-72. doi:10.21508\/1027- 4065-2020-65-5-66-72.","DOI":"10.21508\/1027-4065-2020-65-5-66-72"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Kovalchuk V.P., Nazarchuk O.A., Burkot V.M. et al. Biofilm forming activity of non-fermenting gram-negative bacteria. Wiad Lek., 2021;74(2):252- 256. doi:10.36740\/WLek202102114.","DOI":"10.36740\/wlek202102114"},{"key":"ref9","unstructured":"10. Sidorov A., Mostovoy Y., Slepchenko N. et al. Optimization of adherence to COPD treatment: what results can be achieved? Lek. Obzor. 2021;70(4):156-160."},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Dmytriiev D., Dobrovanov O., Kralinsky K. et al. A case report of successful experience of using adaptive support ventilation in the pediatric patient with viral interstitial pneumonia COVID-19 positive. Lek. Obzor. 2021;70(3):119-123.","DOI":"10.35975\/apic.v25i1.1212"},{"key":"ref11","unstructured":"12. Dmytriiev D., Nazarchuk O., Faustova M. et al. Local anesthetics contributing the struggling biofilm-forming activity of S. aureus colonizing surfaces of venous catheters. Multicenter clinical trial. Lek. Obzor. 2020; 70(1):21-24."},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Dobrovanov O. Efficacy and sensitivity of prenatal and postnatal ultrasound screening of congenital developmental anomalyes of kidneys in Slovakia. Wiad Lek. 2021;74(3 p.I):450-454. doi: 10.36740\/ WLek202103112.","DOI":"10.36740\/wlek202103112"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14. Miller M.R., Hankinson J., Brusasco V. et al. Standardisation of spirometry. Eur Respir J. 2005;26:319\u2013338. doi:10.1183\/09031936.0 5.00034805.","DOI":"10.1183\/09031936.05.00034805"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Wedzicha J.A., Buhl R., Singh D. et al. Tiotropium\/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO\u00ae\/DYNAGITO\u00ae Trials. Adv Ther. 2020;37(10):4266-4279. doi: 10.1007\/s12325-020-01438-3.","DOI":"10.1007\/s12325-020-01438-3"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Palli S.R., Buikema A.R., DuCharme M. et al. Costs, exacerbations and pneumonia after initiating combination tiotropium olodaterol versus triple therapy for chronic obstructive pulmonary disease. J Comp Eff Res. 2019;8(15):1299-1316. doi:10.2217\/cer-2019-0101.","DOI":"10.2217\/cer-2019-0101"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Martinez F.J., Abrahams R.A., Ferguson G.T. et al. Effects of baseline symptom burden on treatment response in COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:181-194. doi: 10.2147\/COPD.S179912.","DOI":"10.2147\/copd.s179912"}],"container-title":["Wiadomo\u015bci Lekarskie"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T17:35:43Z","timestamp":1675272943000},"score":1,"resource":{"primary":{"URL":"https:\/\/wiadlek.pl\/wp-content\/uploads\/archive\/2022\/12\/WLek202212110.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":17,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022]]},"published-print":{"date-parts":[[2022,12]]}},"URL":"https:\/\/doi.org\/10.36740\/wlek202212110","archive":["Internet Archive"],"relation":{},"ISSN":["0043-5147"],"issn-type":[{"value":"0043-5147","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}